Travoprost is under clinical development by Glaukos and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Travoprost’s likelihood of approval (LoA) and phase transition for Ocular Hypertension took place on 09 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 09 Sep 2022 increased Travoprost’s LoA and PTSR for Open-Angle Glaucoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Travoprost Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Travoprost overview

Travoprost is under development for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. It is a prostaglandin analog. It is administered as intraocular implant. The drug candidate is delivered through a micro-invasive glaucoma surgery (MIGS) device using iDose delivery system. The drug candidate along with the titanium implant is capped with a membrane that is designed for continuous controlled drug elution into the anterior chamber. It acts by targeting prostaglandin F2-alpha receptor.

Glaukos overview

Glaukos is an ophthalmic medical device company that research and develops micro technologies to improve glaucoma therapy. The company develops injectable micro-scale therapies to address the complete range of glaucoma disease states and progression. It provides products such as microstent devices to treat glaucoma such as iStent trabecular micro-bypass stent for the treatment of mild- tomoderate open-angle glaucoma. Glaukos’ iStent is used in conjunction with cataract surgery. Glauko’s iStent improves outflow by creating a patent bypass between the anterior chamber and Schlemm’s canal. The company markets its products through a network of distributors in Germany, Canada, the UK, Australia, Brazil and Japan, among others. Glaukos is headquartered in San Clemente, California, the US.

Quick View Travoprost LOA Data

Report Segments
  • Innovator
Drug Name
  • Travoprost
Administration Pathway
  • Intraocular
Therapeutic Areas
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.